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Neurosteroids, comprising pregnane, androstane, and sulfated steroids can alter
neuronal excitability through interaction with ligand-gated ion channels and other
receptors and have therefore a therapeutic potential in several brain disorders. They
can be formed in brain cells or are synthesized by an endocrine gland and reach the
brain by penetrating the blood–brain barrier (BBB). Especially sulfated steroids such as
pregnenolone sulfate (PregS) and dehydroepiandrosterone sulfate (DHEAS) depend on
transporter proteins to cross membranes. In this review, we discuss the involvement of
ATP-binding cassette (ABC)- and solute carrier (SLC)-type membrane proteins in the
transport of these compounds at the BBB and in the choroid plexus (CP), but also
in the secretion from neurons and glial cells. Among the ABC transporters, especially
BCRP (ABCG2) and several MRP/ABCC subfamily members (MRP1, MRP4, MRP8) are
expressed in the brain and known to efflux conjugated steroids. Furthermore, several
SLC transporters have been shown to mediate cellular uptake of steroid sulfates. These
include members of the OATP/SLCO subfamily, namely OATP1A2 and OATP2B1, as
well as OAT3 (SLC22A3), which have been reported to be expressed at the BBB, in
the CP and in part in neurons. Furthermore, a role of the organic solute transporter
OSTα-OSTβ (SLC51A/B) in brain DHEAS/PregS homeostasis has been proposed.
This transporter was reported to be localized especially in steroidogenic cells of the
cerebellum and hippocampus. To date, the impact of transporters on neurosteroid
homeostasis is still poorly understood. Further insights are desirable also with regard
to the therapeutic potential of these compounds.
Keywords: ATP-binding cassette transporters, blood–brain barrier, dehydroepiandrosterone, DHEAS, neuroactive
steroids, pregnenolone sulfate, solute carriers
INTRODUCTION
Neurosteroids are cholesterol-derived compounds categorized in pregnane neurosteroids (e.g.,
allopregnanolone), androstane neurosteroids (e.g., androstanediol), and sulfated compounds
[PregS and DHEAS] (Reddy, 2010). They can be synthesized in the central nervous system,
or the compounds themselves or precursors can be taken up from the systemic circulation
(Baulieu, 1997; Maninger et al., 2009). One of their main functions in the brain is to modulate
Abbreviations: ABC, ATP-binding cassette; BBB, blood–brain barrier; BCRP, breast cancer resistance protein; CP, choroid
plexus; CSF, cerebrospinal fluid; DHEAS, dehydroepiandrosterone sulfate; E1-3-S, estrone-3-sulfate; GABA, γ-aminobutyric
acid; MRP, multidrug resistance protein; NMDA, N-methyl-D-aspartate; OATP, organic anion transporting polypeptide; OST,
organic solute transporter; PregS, pregnenolone sulfate; SULT, sulfotransferase; TRP, transient receptor potential.
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excitability by interaction with membrane receptors and ion
channels (Reddy, 2010). Accordingly, a therapeutic potential
of these compounds or synthetic analogs has been discussed
for a variety of brain disorders (Reddy, 2010). Local steroid
biosynthesis in rodent and human brain has been studied since
1990s (Baulieu, 1997). Expression of key enzymes (e.g., P450 side-
chain cleavage enzyme, P450c17) has been demonstrated in the
principal neurons of several brain areas and in the microglia and
astrocytes (reviewed in: Maninger et al., 2009; Hojo et al., 2011;
Porcu et al., 2016). However, the relative contributions of the
local synthesis and uptake from blood to CNS levels have still
to be clarified and may vary between different neurosteroids. In
contrast to the lipophilic unconjugated compounds, especially
DHEAS and PregS do not diffuse across membranes at a sufficient
rate due to their hydrophilic sulfate moiety. Therefore, this
review focuses on DHEAS/PregS membrane transporters in the
brain. Both compounds play important roles in age-related
memory and learning. They can be formed from the non-sulfated
precursors by SULTs with SULT2B1b as a major isoform in
the human brain (Salman et al., 2011). The ratio of sulfated
versus non-sulfated neurosteroids in the brain may be decisive,
since sulfation can change the direction of the neuromodulating
activity. While for example some non-sulfated neurosteroids such
as allopregnanolone are potent positive modulators of GABA
type A receptors (for review see Chisari et al., 2010; Reddy, 2010),
DHEAS and PregS have been shown to antagonize the GABA
effect on the GABAA receptor (Seljeset et al., 2015) and to be
potent allosteric agonists at NMDA receptors (Wu et al., 1991;
Monnet et al., 1995). Furthermore, PregS has been shown to
directly activate certain TRP channels (Harteneck, 2013).
DHEAS AND PREGS LEVELS IN
PLASMA, BRAIN, AND CEREBROSPINAL
FLUID (CSF) IN HUMANS
While the serum concentrations of the non-sulfated DHEA
and pregnenolone are in the low nM range in men and
women (Labrie et al., 1997; Kancheva et al., 2011), levels of
DHEAS are much higher with a slight difference between men
(2.3–11.5 µM) and women (1.6–6.2 µM). It should be noted
that here total steroid concentrations were measured. Due to
the high plasma protein binding (95% for DHEAS; Wang and
Bulbrook, 1969) the concentration of the unbound steroids is
accordingly lower. Generally, hormone levels decrease with age,
exhibiting a maximum in young men and women (∼20 years;
Labrie et al., 1997). Total PregS serum levels in adolescence
range between 40 and 140 nM, and increase during pregnancy
and at birth (de Peretti and Mappus, 1983; Kancheva et al.,
2011). In contrast to DHEAS and PregS serum levels, less
information is available on their tissue concentrations in the brain
and in the CSF. In the human brain, region-dependent PregS
concentrations between 5 and 40 nmol/kg have been reported
with the highest levels in the striatum and hypothalamus. DHEAS
concentrations were detected in a similar range with the highest
levels in the striatum and cerebellum (Weill-Engerer et al., 2002).
The CSF concentrations of DHEAS and PregS were much lower
compared to the respective serum levels [serum/CSF ratios: 584
(Preg-conjugates), 19849 (DHEA-conjugates); Kancheva et al.,
2011]. These gradients are due to the fact that both compounds
cannot cross the respective barriers by passive diffusion, but
depend on selective uptake and efflux proteins. ABC- and solute
carrier (SLC)-type transporters may not only be relevant for the
transport at the BBB and the blood–CSF barrier in the CP, but
also for secretion of these compounds from neurons and glial cells
(Figure 1).
TRANSPORTERS THAT MAY PLAY
A ROLE IN THE TRANSPORT
OF NEUROSTEROIDS:
ABC TRANSPORTERS
ATP-binding cassette proteins can mediate a unidirectional
primary active transport of a variety of compounds across
membranes. Among the ABC transporters especially ABCG2,
also known as the BCRP, and several ABCC/MRP subfamily
members are known efflux pumps for conjugated steroids (Suzuki
et al., 2003; Haimeur et al., 2004).
BCRP/ABCG2
BCRP/ABCG2 was initially identified as a non-P-glycoprotein
and non-MRP-type resistance factor from drug-selected cell lines
(Doyle et al., 1998; Miyake et al., 1999). Besides anti-cancer
drugs like mitoxantrone, BCRP actively transports sulfated
steroids such as E1-3-S and DHEAS, but not unconjugated or
glucuronidated steroids (Imai et al., 2003; Grube et al., 2007).
The Km value for E1-3-S calculated in isolated membrane vesicles
was in the low µM range (Table 1). In addition, androgens
such as dihydrotestosterone (DHT) have been identified as BCRP
substrates (Huss et al., 2005). In human brain microvessels,
ABCG2/BCRP transcript (Cooray et al., 2002; Warren et al.,
2009) and protein was detected as one of the most abundant ABC
transporters (Shawahna et al., 2011). Immunohistochemistry
showed it primarily localized at the apical (luminal) side of the
endothelial cells (Cooray et al., 2002; Aronica et al., 2005; Warren
et al., 2009). In addition, it was detected in the apical membrane
of the CP epithelium (Roberts et al., 2008a). Hence, BCRP could
be involved in limiting the penetration of peripheral DHEAS and
other steroids into the brain or facilitating the elimination of
brain-derived DHEAS into blood. The apical localization in the
CP, on the other hand, indicate that here BCRP is able to transport
neurosteroids into the CSF.
Members of the MRP/ABCC Family
Anionic conjugates of lipophilic compounds are typical
substrates for several members of the MRP family. As the
founding member, MRP1 (ABCC1) was identified as second
export pump conferring a multidrug resistance phenotype
besides the MDR1/P-glycoprotein (ABCB1) (Cole et al.,
1992). MRP1 was subsequently shown to preferentially
transport amphiphilic anions, especially conjugates of lipophilic
compounds with glutathione, glucuronate, or sulfate (Jedlitschky
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FIGURE 1 | Schematic illustration of ABC and SLC transporters putatively involved in DHEAS and PregS transport and their proposed localization. (A) Structures of
DHEAS and PregS. (B,C) The ABC proteins BCRP (ABCG2), MRP1, MRP4, and MRP8 (ABCC1, ABCC4, and ABCC11), and the solute carriers OAT3 (SLC22A3),
OATP1A2 (SLCO1A2), OATP2B1 (SLCO2B1), and OSTα/ß (SLC51A/B) may be involved in secretion of sulfated steroids from neurons and glial cells and/or in the
transport across the BBB (B) as well as in transport at the blood–CSF barrier in the CP (C). The arrows indicate the directions of substrate transport. Proteins for
which there is little or controversial evidence for expression and localization in the basal or apical membrane are indicated in light orange and by a dashed line.
Concentration gradients of DHEAS and PregS across the BBB and in the CP are schematically indicated at the right side.
et al., 1996; Loe et al., 1996). MRP1 transports in addition certain
cationic or uncharged compounds, but only in co-transport with
reduced glutathione (GSH; Loe et al., 1996). It also mediates the
transport of E1-3-S and of DHEAS in a glutathione-dependent
manner (Qian et al., 2001; Zelcer et al., 2003) and is expressed in
several tissues (Haimeur et al., 2004). It is also expressed in brain
microvessels (Warren et al., 2009); however, the exact localization
and function has not been finally clarified. It was detected to
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TABLE 1 | ABC and SLC transporters possibly involved in neurosteroid transport in the brain.
Transporter CNS expression
(mRNA and protein analysis)
CNS localization
(immunohistochemistry)
Steroid substrates
(Km value)
ABC Transporters
BCRP (ABCG2) mRNA:
− Total brain1
− Isolated brain microvessels (BMV)2,3
Protein:
− BMV (H, M, Mo, R, P)4,5,6,7,8
− Isolated CP9
BBB: apical (luminal) (H, R);
CP: apical (H, R)2,10,11
E1-3-S (6.8 µM)12,13
DHEAS12
DHT14
MRP1 (ABCC1) mRNA:
− Total brain1
− BMV3
− Isolated CP15
Protein:
− Isolated CP (H, R)9,16
BBB: apical (H, B, M),
Basal (abluminal) (R, M);
CP: basal (H, R)17,18,19,20
E1-3-S (+GSH)21
DHEAS (+GSH) (5 µM)22
E2-17βG (1.5 µM)23
MRP4 (ABCC4) mRNA:
− Total brain1
− BMV3
− Isolated CP15
Protein:
− BMV (H, M, Mo, R)4,5,6,7
− Isolated CP9
BBB: apical (H, M, R),
Apical + basal (B);
CP: basal (H, R);
Astrocytes3,11,19,20,24
DHEAS (2 µM)22
E2-17βG (30 µM)22,25
MRP8 (ABCC11) mRNA:
− Total brain1
Neurons (axonal;
cerebellum, cortex)26
E1-3-S (>150 µM)27
DHEAS (13–21 µM)26,27
E2-17βG (63 µM)27
SLC Transporters
OATP1A2 (SLCO1A2) mRNA:
− Total brain1
Protein:
− BMV (M, Mo)5,6
BBB: luminal; amacrine
neurons28,29,30,31
DHEAS (7 µM)32
E1-3-S (16 µM)31
OATP2B1 (SLCO2B1) mRNA:
− Total brain1
Protein:
− Brain capillary cells31 − BMV (M)6
BBB: luminal; CP
(ependymal cells) (R);
amacrine neurons11,29,30,33
E1-3-S (5–21 µM)34,35
DHEAS (9 µM)35 PregS36
OATP3A1 (SLCO3A1) mRNA:
− Total brain1
Protein:
− Isolated CP9
− BMV (P)8
CP; neurons37 E1-3-S38
OAT3 (SLC22A3) mRNA:
− Total brain1
Protein:
− Isolated CP9
− BMV (R)7
BBB: basal (R);
CP: basal (H, R)39,40,11,41
E1-3-S (8.8 µM)42
DHEAS42
OSTα-OSTβ (SLC51A/B) Neurons (cerebellum,
Hippocampus; Purkinje cells)43
DHEAS (1.5 µM)43
PregS (6.9 µM)43
Unless otherwise specified, the data refer to human tissue and transporter protein. B, bovine; BBB, blood–brain barrier (capillary endothelial cells); BMV, isolated brain
microvessels; CP, choroid plexus; DHEAS, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; E1-3-S, estrone-3-sulfate; E2-17βG, estradiol-17β-glucuronide; H,
human; M, mouse; Mo, monkey; P, pig; R, rat; PregS, pregnenolone sulfate. 1Nishimura and Naito, 2005; 2Cooray et al., 2002; 3Warren et al., 2009; 4Shawahna et al.,
2011; 5 Ito et al., 2011; 6Uchida et al., 2011; 7Hoshi et al., 2013; 8Kubo et al., 2015; 9Uchida et al., 2015; 10Aronica et al., 2005; 11Roberts et al., 2008a; 12Grube et al.,
2007; 13 Imai et al., 2003; 14Huss et al., 2005; 15Niehof and Borlak, 2009; 16Gazzin et al., 2008; 17Rao et al., 1999; 18Wijnholds et al., 2000; 19Nies et al., 2004; 20Zhang
et al., 2004; 21Qian et al., 2001; 22Zelcer et al., 2003; 23Jedlitschky et al., 1996; 24Leggas et al., 2004; 25Chen et al., 2001; 26Bortfeld et al., 2006; 27Chen et al., 2005;
28Gao et al., 2000; 29Bronger et al., 2005; 30Gao et al., 2015; 31Lee et al., 2005; 32Kullak-Ublick et al., 1998; 33Ji et al., 2012; 34Pizzagalli et al., 2003; 35Hagenbuch
and Stieger, 2013; 36Grube et al., 2006; 37Huber et al., 2007; 38Tamai et al., 2000; 39Alebouyeh et al., 2003; 40Kikuchi et al., 2003; 41Mori et al., 2003; 42Burckhardt,
2012; 43Fang et al., 2010.
be luminal in humans, bovine, and murine brain (Nies et al.,
2004; Zhang et al., 2004), but also localization at the basolateral
(abluminal) membrane was described in mice and rats (Kilic
et al., 2008; Roberts et al., 2008a). Some groups did not detect
MRP1 protein in human brain capillaries at all (Rao et al., 1999;
Aronica et al., 2005). Because of the inconsistent and low-level
expression, the relevance of this transporter at the BBB is so
far unclear. It may play a more important role in the CP. Here,
MRP1 mRNA was detected in rat and human tissue (Gazzin et al.,
2008; Niehof and Borlak, 2009) and the protein was localized
at the basolateral membrane (Rao et al., 1999; Wijnholds et al.,
2000; Gazzin et al., 2008). Thus, it may be involved in the efflux
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of conjugated steroids from the CSF into blood. In addition,
MRP1 mRNA was detected in cultured rat and human astrocytes
(Hirrlinger et al., 2001; Spiegl-Kreinecker et al., 2002). However,
the protein could not been detected in human glial cells or
neurons in immunohistochemical studies (Nies et al., 2004;
Aronica et al., 2005). MRP1 and MRP2 (ABCC2) share a similar
substrate spectrum, but MRP2 is mainly expressed in polarized
epithelial cells (Keppler, 2011). Immunostaining at the apical
membrane in brain capillaries was described in rats (Miller
et al., 2000), but was not observed in human and bovine brain
(Nies et al., 2004; Zhang et al., 2004). Similarly, MRP3 (ABCC3)
protein was not detected in human brain (Nies et al., 2004).
A more relevant efflux transporter for conjugated steroids in
the brain may be MRP4/ABCC4, which exhibits a unique broad
substrate specificity. MRP4 shows the remarkable capacity to
transport cyclic nucleotides and MRP4 has been established as an
independent regulator of intracellular cAMP levels in several cell
types (Ritter et al., 2005; Jedlitschky et al., 2012; Belleville-Rolland
et al., 2016). Furthermore, MRP4 transports lipid mediators such
as prostanoids and conjugated steroids. DHEAS is transported
by MRP4 in a glutathione-independent manner and with high
affinity (Km of 2 µM; Zelcer et al., 2003). It is expressed in
several tissues especially in the prostate, kidney, blood cells,
and brain (Kool et al., 1997; Haimeur et al., 2004; Nishimura
and Naito, 2005; Niehof and Borlak, 2009; Warren et al., 2009;
Shawahna et al., 2011). Here, it was localized apically in human,
rodent and bovine capillaries (Nies et al., 2004; Leggas et al.,
2004; Zhang et al., 2004; Roberts et al., 2008a). An additional
detection at the basolateral membrane was only described in
bovine brain (Zhang et al., 2004). MRP4 expression was also
detected in human CP (Niehof and Borlak, 2009; Uchida et al.,
2015) and it was localized to the basolateral membrane in human
and murine tissue (Leggas et al., 2004). Moreover, it is expressed
in glial cells. Immunofluorescence studies in the human brain
revealed staining mainly in astrocytes of the subcortical white
matter (Nies et al., 2004). Since glial cells are able to synthesize
neurosteroids, MRP4 may account for the efflux of DHEAS
and other neurosteroids from these cells for a paracrine action.
Astrocytes play a critical role for the development and function of
neurons and these cells in turn are regulated by steroid hormones
as progesterone and DHEA (Acaz-Fonseca et al., 2016; Arbo et al.,
2016). At the BBB and the CP, MRP4 may contribute to the
transport of sulfated steroids from brain and CSF into blood.
A further member of the MRP family, the MRP8 (ABCC11)
may be relevant with respect to neurosteroid transport. MRP8
was shown to transport DHEAS in isolated membrane vesicles
with a Km value of 13–21 µM, whereas the Km was above
150 µM for MRP8-mediated transport of E1-3-S (Chen et al.,
2005; Bortfeld et al., 2006). In immunofluorescence studies, it
was detected preferentially in the white matter of the cortex
and cerebellum and co-localized with neurofilaments indicating
localization in neuronal axons (Bortfeld et al., 2006). In addition,
weak immunostaining was detected in the gray matter and also in
the axons of peripheral neurons. The axonal localization implies
that MRP8 can mediate presynaptic efflux of neurosteroids
from neurons and thus could directly participate in modulating
postsynaptic neurotransmitter receptors (Bortfeld et al., 2006).
Uptake (SLC) Transporters
Besides ABC-type efflux transporters, neurosteroid
concentrations in the brain may also be modulated by uptake
transporters. Since several members of the SLC superfamily have
been identified as uptake transporters for steroid conjugates in
general, these transporters are interesting candidates for the
transport of neurosteroids. In fact, several SLCs have been shown
to mediate cellular uptake of DHEAS and PregS.
Members of the OATP/SLCO Family
Among the SLC transporters, the OATP (SLCO) family is
probably the most interesting one in this context. In humans, 11
SLCO transporters exist, organized in six families (Hagenbuch
and Stieger, 2013). The physiological substrate profile of the
OATP transporters comprises a wide variety of endogenous
organic anions including bile acids, bilirubin, thyroid hormones,
and prostaglandins (Hagenbuch and Stieger, 2013). In addition,
OATPs transport steroid hormone conjugates like E1-3-S (nearly
all OATPs) or estradiol-17β-glucuronide (OATP1A2, OATP1B1,
OATP1B3, OATP1C1, and OATP4A1) and the neurosteroid
DHEAS (OATP1A2, OATP1B1, OATP1B3, and OATP2B1)
(Hagenbuch and Stieger, 2013). The affinity of these transporters
toward DHEAS was slightly above (OATP1B1 and OATP1B3)
or in the range (OATP2B1 and OATP1A2) (Table 1) of
the physiological plasma concentration (1.6–11.5 µM; Labrie
et al., 1997) indicating an in vivo relevance of these findings.
OATP1B1 and OATP1B3 are almost exclusively expressed in
the human liver. Here, they are responsible for cellular uptake
as a prerequisite for hepatic metabolism and elimination. In
turn, the expression and function of these transporters affect
systemic DHEAS levels as shown by enhanced DHEAS levels
in monkeys and rats after treatment with the unspecific OATP
inhibitor rifampicin (Watanabe et al., 2015; Nishizawa et al.,
2017). Assuming a DHEAS transport/uptake from the blood into
the brain/CSF (Kancheva et al., 2010), changes in DHEAS plasma
concentration might indirectly influence the concentration in
these compartments. Therefore, OATPs localized in the BBB
and/ or the CP are of special interest. Indeed, OATP1A2,
OATP1C1, OATP2B1, and OATP3A1 have been detected in
these structures in humans (Kullak-Ublick et al., 1998; Pizzagalli
et al., 2002; Huber et al., 2007; Roberts et al., 2008b; Ji et al.,
2012). Since OATP1C1 is a thyroid hormone transporter and
the function of OATP3A4 is only poorly understood, at present
OATP1A2 and OATP2B1 are probably the most interesting
members concerning neurosteroid transport in the brain. Both
proteins are expressed in the endothelial cells of the BBB
presumably in the luminal membrane predisposing them as
transporters for uptake into the brain (Gao et al., 2000; Bronger
et al., 2005; Lee et al., 2005). In addition, OATP1A2 and
OATP2B1 are also expressed in other CNS cell types. While
both transporters have been identified in amacrine neurons of
the retina, OATP1A2 was additionally found in hippocampal
pyramidal and granule cells (Gao et al., 2015). Besides DHEAS,
PregS levels in the brain may also be influenced by uptake
transporters in the BBB, even though plasma concentrations
of PregS were up to two orders of magnitude below the
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DHEAS levels (Sanchez-Guijo et al., 2015). Like for DHEAS,
OATP-transporters are interesting candidates in this context.
While PregS significantly inhibits OATP2B1 function (St Pierre
et al., 2002; Grube et al., 2006) first reports indicated no direct
transport of PregS by this transporter (Pizzagalli et al., 2003;
Grube et al., 2006). Interestingly, OATP2B1-mediated transport
of E1-3-S and DHEAS was stimulated by steroid hormones like
progesterone (Grube et al., 2006; Koenen et al., 2012). Under
these conditions, PregS was also transported by OATP2B1 (Grube
et al., 2006). PregS transport by other OATPs has not been
studied so far. With regard to the CP only limited information
is available about OATP expression and function in humans. In
a recent LC-MS/MS-based study examining transporter protein
expression in this structure, only OATP3A1 was detected, while
OATP1A2 and OATP1C1 were below the detection limit and
OATP2B1 was not analyzed (Ji et al., 2012). This finding was
quite surprising, since in animal models several OATPs have been
detected in the CP and shown to be involved in the neurosteroid
transport into the liquor (Asaba et al., 2000; Choudhuri et al.,
2003; Ji et al., 2012). Due to the limited information available, the
significance of OATP3A1 in this context cannot be conclusively
assessed. However, a transport of E1-3-S has also been shown
for the OATP3A1 and two splice variants of the transporter are
selectively expressed in the apical and basal membrane of the
ependymal cells of the CP (Tamai et al., 2000; Huber et al., 2007).
Other Organic Anion Transporters
(OSTα-OSTβ, OATs)
Besides OATPs, an interaction of neurosteroids (mainly DHEAS
and PregS) with several further organic anion transporters
has been reported. For example, both sulfated neurosteroids
have been shown to be transported with high affinity by the
organic solute transporter OSTα-OSTβ [Km: 1.5 µM (DHEAS)
and 6.9 µM (PregS)] (Fang et al., 2010). The heterodimer
OSTα-OSTβ is a relatively new member of the SLC family
(SLC51) and encoded by two genes (SLC51A and SLC51B).
Like OATPs, the transport mechanism is facilitated diffusion;
therefore OSTα-OSTβ-mediated transport is dependent on the
electrochemical gradient of its substrates (Ballatori et al., 2013).
In the human brain, the transporter is expressed in Purkinje cells
and hippocampal neurons (Fang et al., 2010). Both regions are
well known for their function in the process of learning and
memory, and hippocampal neurons have been suggested as a
target site for PregS action (Akwa et al., 2001).
A third group of SLC transporters involved in the CNS
distribution of sulfated neurosteroids are the organic anion
transporters (OATs), which are part of the SLC22A branch
(Burckhardt, 2012). The pivotal role of these transporters is the
excretion of water-soluble organic anions in the kidney. However,
selected members are also present in other organs including the
brain (Burckhardt, 2012). In the brain OAT3, is probably the most
interesting member of this family. The transporter is expressed
in the BBB as well as the CP (Alebouyeh et al., 2003; Kikuchi
et al., 2003; Uchida et al., 2015). In a mouse model, OAT3 was
characterized as the DHEAS transporter in part responsible for
the DHEAS efflux across the BBB (Miyajima et al., 2011). Besides
OAT3, mRNA expression of OAT1 and OAT2 has also been
shown for the human brain (Lopez-Nieto et al., 1997; Alebouyeh
et al., 2003; Cropp et al., 2008); however, protein data for these
transporters are limited.
CONCLUSION AND PERSPECTIVES
The detailed functions of the described ABC and SLC
transporters in brain are still poorly understood. Even data
on the expression and localization, e.g., at the BBB are often
controversial. Knock-out mice of the ABC and some SLC
transporters are available, but have been mainly used to study
the role of these transporters for brain penetration of certain
drugs (Dallas et al., 2006; Chaves et al., 2014). These studies
are in part hampered by overlapping substrate specificities of
several transporters and with respect to neurosteroids by the
fact of negligible levels of sulfated steroids in rodent brain
(Liu et al., 2003; Liere et al., 2009). Furthermore, a number
of functional genetic variants in several transporter genes are
known (Bruhn and Cascorbi, 2014); however, their impact on
neurosteroid transport is so far largely unknown. Variations in
transporter function may affect concentrations and action of
several neurosteroids in brain. Therefore, a better understanding
of these processes is an important aspect also in the context of a
possible therapeutic use of these compounds.
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